Evidence supporting the use of: Coenzyme Q10 (CoQ10)
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Coenzyme Q10 (CoQ10) is supported by scientific evidence for use as an adjunct in the management of congestive heart failure (CHF), though the strength of evidence is moderate. CoQ10 is a naturally occurring antioxidant found in mitochondria, where it plays a crucial role in cellular energy production (ATP synthesis). In patients with CHF, myocardial CoQ10 levels are often reduced, which may impair cardiac energy metabolism and contribute to symptoms. Several randomized controlled trials and meta-analyses have explored CoQ10 supplementation in CHF. Notably, the 2014 Q-SYMBIO trial demonstrated that long-term CoQ10 supplementation (100 mg three times daily) in patients with moderate to severe heart failure resulted in a significant reduction in major adverse cardiovascular events and mortality compared to placebo. Other studies and meta-analyses have reported improvements in ejection fraction, exercise capacity, and symptoms, though some trials have shown mixed results and the effects are generally considered modest. CoQ10 is well-tolerated with a favorable safety profile. While it is not a replacement for guideline-directed medical therapy, several professional organizations (such as the European Society of Cardiology) note that CoQ10 may be considered as an adjunctive therapy in selected patients. In summary, there is moderate scientific validation for using CoQ10 in CHF, mainly as a supportive supplement rather than a primary therapy.

More about coenzyme Q10 (CoQ10)
More about Congestive Heart Failure